ResearcherInsermActive in the last 2 years
Anne‐Laure Védié
Matched on ORCID iD 0009-0007-0403-4960; OpenAlex author ID A5045388369. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 35
2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper
Papers 5
- Comparison of radiological and pathological tools to assess response to neoadjuvant treatment in resected pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1177/17588359251403909↗
- Childhood and adulthood passive and active smoking, and the ABO group as risk factors for pancreatic cancer in women. Co-author DOI 10.1002/ueg2.12487↗
- Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective… Co-author DOI 10.1016/j.ejca.2024.115051↗
- Pancreatic cancer: Best supportive care. Co-author DOI 10.1016/j.lpm.2019.02.032↗
- Lifetime and baseline alcohol intakes and risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition study. Co-author DOI 10.1002/ijc.31367↗
Closest collaborators
The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Vinciane Rebours · 3 shared papers, 2018–2025 · strength 0.53
- Paper Childhood and adulthood passive and active smoking, and the ABO group as risk factors for pancreatic cancer in women. DOI 10.1002/ueg2.12487↗
- Paper Comparison of radiological and pathological tools to assess response to neoadjuvant treatment in resected pancreatic du… DOI 10.1177/17588359251403909↗
- Paper Lifetime and baseline alcohol intakes and risk of pancreatic cancer in the European Prospective Investigation into Canc… DOI 10.1002/ijc.31367↗
- Louis de Mestier · 2 shared papers, 2024–2025 · strength 0.38
- Paper Comparison of radiological and pathological tools to assess response to neoadjuvant treatment in resected pancreatic du… DOI 10.1177/17588359251403909↗
- Paper Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination de… DOI 10.1016/j.ejca.2024.115051↗
- Maxime Ronot · 1 shared paper, 2025 · strength 0.22
- Safi Dokmak · 1 shared paper, 2025 · strength 0.22
- Jerome F. Cros · 1 shared paper, 2025 · strength 0.22
- Anne Couvelard Benveniste · 1 shared paper, 2025 · strength 0.22
- Alain Sauvanet Sauvanet · 1 shared paper, 2025 · strength 0.22
- Anaïs Jenvrin · 1 shared paper, 2025 · strength 0.22
- Cindy Neuzillet · 1 shared paper, 2019 · strength 0.20
- Jeannie M'Baloula · 1 shared paper, 2024 · strength 0.16
- Anna Pellat · 1 shared paper, 2024 · strength 0.16
- Jean‐Frédéric Blanc · 1 shared paper, 2024 · strength 0.16
- Marie Müller · 1 shared paper, 2024 · strength 0.16
- Anthony Turpin · 1 shared paper, 2024 · strength 0.16
- Solène Doat · 1 shared paper, 2024 · strength 0.16
- Isabelle Trouilloud · 1 shared paper, 2024 · strength 0.16
- Alice Boilève · 1 shared paper, 2024 · strength 0.16
- Julien Taı̈eb · 1 shared paper, 2024 · strength 0.16
- David Tougeron · 1 shared paper, 2024 · strength 0.16
- François‐Xavier Caroli‐Bosc · 1 shared paper, 2024 · strength 0.16
- Olivier Bouché · 1 shared paper, 2024 · strength 0.16
- H. Bas Bueno-de-Mesquita · 1 shared paper, 2018 · strength 0.05
- Eric J. Duell · 1 shared paper, 2018 · strength 0.05
- Elio Ríboli · 1 shared paper, 2018 · strength 0.05
- María‐Dolores Chirlaque · 1 shared paper, 2018 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.